Shortage of Ryzodeg 70/30 FlexTouch insulin prefilled pens 8 July 2023 The Therapeutic Goods Administration (TGA) has advised of a current shortage of Ryzodeg 70/30 FlexTouch insulin prefilled pens. The shortage is expected to continue until mid-next year. To help manage the shortage, pharmacists can give people living with diabetes Ryzodeg 70/30 Penfill cartridges instead of Ryzodeg 70/30 FlexTouch prefilled pens under certain conditions. Both products contain the same medicine, at the same strength, have the same storage requirements, and are administered by injection under the skin (subcutaneous injection). However, the device used to administer the medicine is different. If you have been prescribed Ryzodeg 70/30 FlexTouch insulin prefilled pens, it’s important to speak with your pharmacist, doctor, diabetes educator or nurse who can explain to you the differences between FlexTouch prefilled pens and Penfill cartridges, how to administer them, and provide you a new delivery device (a NovoPen) for free. The TGA website provides additional information about the shortage and guidance for users of Ryzodeg 70/30 FlexTouch insulin prefilled pens.
Blog 22 September 2023 Q&A on Fiasp Penfill listing on the PBS On 18 September, Minister for Health and Aged Care, Hon Mark Butler MP, announced that Fiasp insulin will continue to... Continue Reading
News 18 September 2023 Fiasp insulin to remain on the Pharmaceutical Benefits Scheme Diabetes Australia has welcomed the announcement by Minister for Health and Aged Care, Hon Mark Butler MP, that Fiasp insulin will continue to be available on the Pharmaceutical Benefits Scheme (PBS) from 1 October 2023. Continue Reading
News 17 August 2023 Update on Fiasp insulin Diabetes Australia have been consistently talking with both the Federal Government and Novo Nordisk about the need for a solution before 1 October 2023. Continue Reading